Immix Biopharma Announces 100% Overall Response Rate And 70% Complete Response; 23.7 Months Best Response Duration (Ongoing) For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis Patients At ASH 2023
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma, Inc. (IMMX) reported a 100% overall response rate and 70% complete response rate for its CAR-T therapy NXC-201 in a Phase 1b/2a study for relapsed/refractory AL Amyloidosis patients. The best response duration was 23.7 months and ongoing as of December 10, 2023. The study was presented at the 65th American Society of Hematology Meeting. NXC-201 is the first CAR-T in clinical development for AL amyloidosis and has received Orphan Drug Designation by the FDA. The prevalence of the disease is growing by 12% per year, with an estimated 29,712 patients in 2023. The Amyloidosis market is expected to reach $6 billion by 2025.
December 11, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's NXC-201 demonstrated strong efficacy in a Phase 1b/2a study for AL Amyloidosis, with a 100% overall response rate and 70% complete response rate. The therapy is the first CAR-T in clinical development for this condition and has FDA Orphan Drug Designation.
The positive clinical trial results for NXC-201 are highly relevant and important for Immix Biopharma as they indicate potential for a successful product in a growing market. The data could lead to increased investor confidence and a positive short-term impact on IMMX's stock price, given the unmet medical need and the Orphan Drug Designation which could facilitate a faster path to market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100